Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Profit After Tax: 2019-2025

Historic Profit After Tax for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Profit After Tax fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$805.7 million, marking a year-over-year decrease of 80.53%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Profit After Tax of -$184.9 million as of Q3 2025, which was down 0.64% from -$183.8 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Profit After Tax peaked at -$2.6 million during Q2 2022, and registered a low of -$267.4 million during Q4 2024.
  • Moreover, its 3-year median value for Profit After Tax was -$169.6 million (2025), whereas its average is -$157.7 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Profit After Tax soared by 97.49% in 2022, and later slumped by 6,179.91% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Profit After Tax (Quarterly) stood at -$152.3 million in 2021, then climbed by 7.69% to -$140.6 million in 2022, then decreased by 21.17% to -$170.3 million in 2023, then tumbled by 56.98% to -$267.4 million in 2024, then dropped by 12.59% to -$184.9 million in 2025.
  • Its last three reported values are -$184.9 million in Q3 2025, -$183.8 million for Q2 2025, and -$169.6 million during Q1 2025.